Siga Technologies Inc income statement
In fiscal 2025, Siga Technologies Inc reported revenue of $94.6m, down 31.8% on the year before, operating income of $23.7m (a 25.1% margin) and net income of $23.3m, or $0.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 | 12 | 477 | 27 | 125 | 134 | 111 | 140 | 139 | 95 | 54 |
| Cost of revenue | 0 | 0 | 95 | 2 | 15 | 17 | 10 | 18 | 31 | 30 | 24 |
| Gross profit | 15 | 12 | 382 | 25 | 110 | 117 | 100 | 122 | 107 | 65 | 29 |
| Research and development | 20 | 17 | 13 | 13 | 11 | 10 | 23 | 16 | 12 | 20 | 20 |
| Selling, general and administrative | 14 | 12 | 13 | 13 | 15 | 18 | 35 | 22 | 25 | 21 | 20 |
| Operating income | −31 | −19 | 355 | −2 | 85 | 89 | 43 | 84 | 70 | 24 | −11 |
| Interest expense | 2 | 15 | 15 | 16 | 3 | 0 | 0 | — | — | — | — |
| Income before tax | −40 | −38 | 412 | −10 | 74 | 89 | 44 | 88 | 76 | 30 | −6 |
| Income tax | 0 | −2 | −10 | −3 | 17 | 20 | 10 | 20 | 17 | 7 | −3 |
| Net income | −40 | −36 | 422 | −7 | 56 | 69 | 34 | 68 | 59 | 23 | −3 |
| Diluted EPS | −$0.69 | −$0.46 | $5.18 | −$0.15 | $0.71 | $0.91 | $0.46 | $0.95 | $0.82 | $0.32 | −$0.04 |
| Diluted shares (average) | 57m | 79m | 83m | 82m | 79m | 76m | 74m | 72m | 72m | 72m | 72m |
| EBITDA | −31 | −19 | 355 | −2 | 85 | 90 | 43 | 84 | 71 | 24 | −11 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 81 | 7 | 81 | 3 | 4 | 6 | 41 |
| Cost of revenue | 2 | 14 | 0 | 26 | 1 | 3 | 3 | 18 |
| Gross profit | 8 | 67 | 7 | 56 | 2 | 1 | 3 | 23 |
| Research and development | 3 | 3 | 3 | 4 | 7 | 5 | 4 | 4 |
| Selling, general and administrative | 5 | 7 | 6 | 5 | 5 | 5 | 5 | 5 |
| Operating income | 1 | 57 | −2 | 46 | −10 | −9 | −5 | 14 |
| Income before tax | 2 | 59 | −1 | 47 | −8 | −8 | −4 | 15 |
| Income tax | 1 | 13 | −0 | 12 | −2 | −3 | −1 | 2 |
| Net income | 1 | 46 | −0 | 35 | −6 | −5 | −3 | 12 |
| Diluted EPS | $0.02 | $0.63 | −$0.01 | $0.49 | −$0.09 | −$0.08 | −$0.05 | $0.17 |
| EBITDA | 1 | 57 | −2 | 46 | −10 | −9 | −5 | 14 |
Compare with peers
- Tango Therapeutics, Inc. income statement
- Gossamer Bio, Inc. income statement
- Nektar Therapeutics income statement
- Ocular Therapeutix, Inc income statement
- Invivyd, Inc. income statement
Head to head: SIGA vs TNGXGOSS vs SIGANKTR vs SIGAOCUL vs SIGA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies